Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bausch & Lomb

This article was originally published in The Gray Sheet

Executive Summary

Firm commences hostile takeover bid for tinted contact lens maker Wesley Jessen April 3 via $34-per-share tender offer (1"The Gray Sheet" April 3, In Brief). Separately, B&L filed a lawsuit in the Court of Chancery of Delaware against Wesley Jessen and Ocular Sciences seeking "injunctive relief" against the Wesley Jessen/Ocular Sciences merger agreement of March 20, redemption of Wesley Jessen's "poison pill" anti-takeover provisions and "a declaration that any breakup fee Ocular receives it holds as a constructive trustee," B&L states

You may also be interested in...

Ocular Sciences v. Bausch & Lomb

Lawsuit filed in California state court seeks injunctive relief, compensatory and punitive damages from Bausch & Lomb for tortious interference with the March 20 definitive merger agreement between Ocular and Wesley Jessen. The suit is the latest salvo in a tug of war for Wesley Jessen. B&L launched a hostile $34-per-share takeover bid for Wesley Jessen April 3 and filed a lawsuit against Wesley Jessen and Ocular seeking injunctive relief against the merger in the Court of Chancery of Delaware (1"The Gray Sheet" April 10, In Brief)

Canada Allows Exceptional Drug, Device Imports To Tackle COVID-19 Shortages

Medical products that do not fully comply with Canadian requirements but are manufactured according to comparable standards are being allowed into the country to deal with COVID-19-related shortages.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts